FOLR1 and neoplasm: Although studies involving FRα-targeted therapies with antibodies (such as farletuzumab) [111,112,113,114], antibody-drug conjugates (such as mirvetuximab soravtansine) [119], or drug conjugates (such as EC145) [5] combined with high frequency FRα expression have established FRα as a viable and tumor-specific approach for treating EOC, clinical results have been mixed [110,115,116,118,120,124,125].